Anti-VEGF [VG-1]
Invented by Helen Turley from University of Oxford
Invented at University of Oxford
- Datasheet
- References (12)
- Inventor Info
Info
| Catalogue Number | 151258 |
| Applications | ELISA IHC IF IP WB |
| Antigen/Gene or Protein Targets | Vascular Endothelial Growth Factor (VEGF) |
| Reactivity | Human |
| Relevance |
Monoclonal antibody targeted at vascular endothelial growth factor (VEGF) is valuable for investigating VEGF and angiogenesis in pathological conditions particularly within cancer. Background and Research Application VG-1 monoclonal antibody is directed against vascular endothelial growth factor (VEGF) isoforms 121, 165 and 189. VEGF is a 34-43 kD polypeptide growth factor, part of the PDGF family. There are 7 homo-dimeric isoforms (A-G) with VEGF 121, VEGF 165 and VEGF189 being the most extensively studied (F,D and B respectively). They are generated by alternative splicing and bind to VEGF receptors (FLT-1 and KDR) which are selectively expressed on vascular endothelial cells. VEGF elicits mitogenic effects on endothelial cells and is strongly angiogenic, with a role in cancer and metastasis. VEGF is involved in vasculogenesis and endothelial growth. The VEGF expression is potentiated and the protein is secreted by tumour cells in response to hypoxia, by activated oncogenes, growth factors, nitric oxide and a variety of cytokines. VEGF is an angiogenic growth factor and a prognostic indicator for cancer when detected in serum. VG-1 is useful for studies of VEGF and angiogenesis in human pathological material. Anti VG-1 was created to investigate the tissue distribution of VEGF in normal and pathological specimens with a stable and reliable reagent. |
| Host | Mouse |
| Immunogen | Recombinant VEGF Protein |
| Immunogen UniProt ID | P15692 |
| Positive Control | Corpus luteum, VEGF165 recombinant protein, astrocytoma or hemoangiosarcoma. |
| Subclass | IgG1 |
| Molecular Weight (kDa) | 19-22 |
| Myeloma Used | P3/NS1/1-Ag4.1 |
| Recommended Growing Conditions | IMDM + 15% FCS (HAT may be required) to recover.DMEM + 10% FCS |
| Strain | Balb/c |
| Notes |
Production Details Purified using multi-step affinity chromatography with protein A. Storage Conditions Store at -20 degrees frozen. Avoid repeated freeze/thaw cycles. Points of Interest VG-1 detects the 121, 165 and 185 VEGF isoforms in fixed specimens. Anti VG-1 performs well on paraffin-embedded material on both transfected material and tissue sections. It has been used to differentiate between disease states for therapeutic path assessment (e.g. if VEGF present bevacizumab added to cancer therapy). Anti VG-1 can be used to understand the distribution and role of VEGF in disease, such as cancer, which in turn can be used to further therapeutics development. When using anti VG-1 in immunohistochemical staining, normal tissues has strong staining of endometrial and salivary glands, and of the mucosa of the GI tract. In tumours, a percentage of neoplastic cells of lung, breast and melanoma cancers were labelled. In both normal and neoplastic tissues, large VEGF staining was seen in plasma of veins and stroma. In the CNS, Purkinje cells of the neonatal cerebellum were labelled but this was not seen in adult cerebellum. Concentration 1mg/ml as standard |
| Research Area | Cancer, Cardiovascular, Cell Signaling & Signal Transduction, Metabolism |
References: 12 entries
Argyris et al. 2019. Oral Oncol. 95:1-10. PMID: 31345374.
Lan et al. 2018. Int J Radiat Oncol Biol Phys. 101(1):74-87. PMID: 29619980.
Xu et al. 2017. Mol Med Rep. 16(6):8755-8762. PMID: 29039481.
Novo et al. 2015. Gynecol Oncol Rep. 14:26-30. PMID: 26793768.
The role of bone marrow mesenchymal stem cells in the treatment of acute liver failure.
Europe PMC ID: 24312909
Yuan et al. 2013. Biomed Res Int. 2013:251846. PMID: 24312909.
Giatromanolaki et al. 2003. J Pathol. 200(2):222-8. PMID: 12754744.
DEC1 (STRA13) protein expression relates to hypoxia- inducible factor 1-alpha and carbonic anhydrase-9 overexpression in non-small cell lung cancer.
Europe PMC ID: 12754744
Hui et al. 2002. Clin Cancer Res. 8(8):2595-604. PMID: 12171890.
Coexpression of hypoxia-inducible factors 1alpha and 2alpha, carbonic anhydrase IX, and vascular endothelial growth factor in nasopharyngeal carcinoma and relationship to survival.
Europe PMC ID: 12171890
Turley et al. 1998. J Pathol. 186(3):313-8. PMID: 10211122.
Expression of VEGF in routinely fixed material using a new monoclonal antibody VG1.
Europe PMC ID: 10211122
Add a reference
References: 12 entries
Argyris et al. 2019. Oral Oncol. 95:1-10. PMID: 31345374.
Lan et al. 2018. Int J Radiat Oncol Biol Phys. 101(1):74-87. PMID: 29619980.
Xu et al. 2017. Mol Med Rep. 16(6):8755-8762. PMID: 29039481.
Novo et al. 2015. Gynecol Oncol Rep. 14:26-30. PMID: 26793768.
The role of bone marrow mesenchymal stem cells in the treatment of acute liver failure.
Yuan et al. 2013. Biomed Res Int. 2013:251846. PMID: 24312909.
Giatromanolaki et al. 2003. J Pathol. 200(2):222-8. PMID: 12754744.
DEC1 (STRA13) protein expression relates to hypoxia- inducible factor 1-alpha and carbonic anhydrase-9 overexpression in non-small cell lung cancer.
Hui et al. 2002. Clin Cancer Res. 8(8):2595-604. PMID: 12171890.
Coexpression of hypoxia-inducible factors 1alpha and 2alpha, carbonic anhydrase IX, and vascular endothelial growth factor in nasopharyngeal carcinoma and relationship to survival.
Turley et al. 1998. J Pathol. 186(3):313-8. PMID: 10211122.
Expression of VEGF in routinely fixed material using a new monoclonal antibody VG1.
Add a reference
